Home > Healthcare > Pharmaceuticals > Finished Drug Form > heparin market
Get a free sample of Heparin Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Heparin Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Recent advancements in hemodialysis have created lucrative opportunities for market progression. These advancements have increased the demand for high-flux dialyzers, which enhance clearance rates for toxins and fluid removal and require longer treatment times. To prevent clotting in the dialysis circuit during these prolonged treatments, heparin is commonly used as an anticoagulant. Researchers are actively exploring and developing heparin-sparing techniques in hemodialysis, which will positively impact industry expansion.
In 2022, the heparin industry size was valued at more than USD 4.8 billion in 2022 and will grow at over 2.5% CAGR from 2023 to 2032, attributed to the growing occurrence of chronic disorders globally.
The low molecular weight heparin industry was worth over USD 4.2 billion in 2022, owing to the rising prevalence of deep vein thrombosis.
Major heparin industry players include Amphastar, Leo Pharma, Rovi, Sanofi, Changzhou Qianhong Biopharma, Pfizer, Shenzhen Hepalink, and Nanjing King-Friend Biochemical Pharmaceutical, among others.
Europe heparin market held more than 58.5% market share in 2022, on account of the surging prevalence of venous thromboembolism, ischemic heart disease, and other cardiovascular diseases that lead to blood clot formation in the region.